Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.72 USD
-0.64 (-0.73%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $86.73 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth C Momentum B VGM
Zacks News
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $61.55 in the latest trading session, marking a -0.92% move from the prior day.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal
by Zacks Equity Research
The NIAID's ACTIV-5/BET-B study evaluating Humanigen's (HGEN) lenzilumab plus remdesivir in hospitalized COVID-19 patients fails to meet the primary endpoint. Stock down.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Gilead Sciences (GILD) Stock Moves -0.51%: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $62.34, marking a -0.51% move from the previous day.
VERU's Shares Jump on Successful COVID-19 Study Results
by Zacks Equity Research
VERU gains on the success of its late stage study evaluating the efficacy and safety of oral sabizabulin 9 mg for COVID-19.
Zacks Market Edge Highlights: ExxonMobil, Chevron, Philip Morris International, Gilead Sciences and General Mills
by Zacks Equity Research
ExxonMobil, Chevron, Philip Morris International, Gilead Sciences and General Mills are part of Zacks Market Edge blog.
Q2 Earnings: Energy and What Else?
by Tracey Ryniec
Expectations are low for this earnings season. Will companies surprise the Street?
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $62.34, moving -0.03% from the previous trading session.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Pfizer (PFE) Seeks FDA Nod for Its Oral Antiviral COVID Pill
by Zacks Equity Research
Pfizer (PFE) submits NDA to the FDA seeking approval for using its oral antiviral COVID pill in vaccinated and unvaccinated patients at a high risk of developing severe COVID-19 complications.
Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More
by Zacks Equity Research
Regulatory and other updates from Epizyme (MRNA) and Kezar (KZR) are a few key highlights from the biotech sector during the past week.
Gilead's (GILD) Yescarta Gets EC Nod for Follicular Lymphoma
by Zacks Equity Research
Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.
Gilead Sciences (GILD) Stock Moves -0.99%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $62.21 in the latest trading session, marking a -0.99% move from the prior day.
Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA
by Zacks Equity Research
Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.
Gilead (GILD) HIV Candidate Gets Positive CHMP Recommendation
by Zacks Equity Research
Gileads (GILD) lenacapavir gets a positive CHMP opinion for the treatment of HIV-1 infection.
Bristol Myers (BMY) Breyanzi Gets FDA Nod for Label Expansion
by Zacks Equity Research
Bristol Myers' CAR T cell therapy Breyanzi was approved by the FDA for relapsed or refractory large B-cell Lymphoma after one prior therapy.
Gilead (GILD) Announces Positive Data on Hepcludex for HDV
by Zacks Equity Research
Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.
Top Stock Reports for Tesla, Broadcom & Anthem
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Broadcom Inc. (AVGO), and Anthem, Inc. (ANTM).
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $61.51, moving +1.65% from the previous trading session.
Gilead Sciences (GILD) Stock Moves -1.15%: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $57.72, marking a -1.15% move from the previous day.
Pfizer (PFE) COVID Pill Ineffective in Standard Risk Patients
by Zacks Equity Research
Pfizer (PFE) stops enrolling patients in a phase II/III study evaluating its COVID pill in standard-risk population after new data from this study showed that it is not all statistically significant.
Gilead Sciences (GILD) Stock Moves -0.72%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed the most recent trading day at $60.74, moving -0.72% from the previous trading session.
Why Is Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report?
by Zacks Equity Research
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biogen Inc. (BIIB) Down 4.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.